Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Regulatory CD4+CD25+Foxp3+ T lymphocytes (Tregs) are a specialized subpopulation of CD4+ T cells that play a critical role in maintaining immune system balance. They suppress the activation and proliferation of other immune cells to prevent excessive or misdirected immune responses. Tregs are characterized by the expression of the surface markers CD4 and CD25 and the transcription factor Foxp3, which is essential for their development and function. They are crucial for maintaining peripheral tolerance and preventing autoimmune diseases. Tregs employ several mechanisms to exert their immunosuppressive effects, including secretion of inhibitory cytokines, induction of apoptosis in effector cells, modulation of dendritic cell function, and production of immunosuppressive adenosine.
Immunosuppression via cytokine secretion (IL-10, TGF-beta, IL-35), cytolysis (Granzyme B), metabolic disruption (CD39/CD73), and modulation of dendritic cell function.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Regulatory CD4+CD25+Foxp3+ T Lymphocytes (Tregs).